Lexeo Therapeutics, Inc. Common Stock (LXEO) Financials

LXEO Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 254.9 million 19.8 million
March 31, 2026 250.4 million 18.9 million
Dec. 31, 2025 268.7 million 22.0 million
Sept. 30, 2025 143.8 million 23.0 million

LXEO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -17.6 million 5.7 million
March 31, 2026 -21.2 million 2.8 million
Dec. 31, 2025 -20.1 million 2.7 million
Sept. 30, 2025 -29.8 million 2.7 million

LXEO Net Income

No data available :(

LXEO Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 211.7 million - -
March 31, 2026 71.8 million - 7.4 million
Dec. 31, 2025 181.8 million - 7.9 million
Sept. 30, 2025 41.0 million - 8.5 million

LXEO Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 85.6 million
March 31, 2026 81.2 million
Dec. 31, 2025 76.4 million
Sept. 30, 2025 61.0 million

LXEO Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 7000 19.0 million 9.0 million -
March 31, 2026 35000 15.7 million 6.6 million -
Dec. 31, 2025 - 16.2 million 6.9 million -
Sept. 30, 2025 289000 15.7 million 6.0 million -

LXEO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 546000
Dec. 31, 2025 - 538000
Sept. 30, 2025 - 530000

LXEO

Price: $5.06

52 week price:
3.99
10.99

Earnings Per Share: -0.88 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 440.6 million

Links: